Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Molecular Genetics |
RCV001375012 | SCV001572300 | uncertain significance | Neurodevelopmental disorder | 2021-03-31 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV003315448 | SCV004047157 | uncertain significance | Combined oxidative phosphorylation defect type 21 | criteria provided, single submitter | clinical testing | The c.1036C>T (p.Arg346Cys) missense variant in TARS2 gene has been submitted to ClinVar as a Variant of Uncertain Significance (VUS), but no details are available for independent assessment. It has not been reported in affected individuals. This variant is reported with the allele frequency (0.0003%) in the gnomad and novel in 1000 genome database. The amino acid Arg at position 346 is changed to a Cys changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Arg346Cys in TARS2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Variant of Uncertain Significance (VUS). | |
Houlden Lab, |
RCV003315448 | SCV003035495 | likely pathogenic | Combined oxidative phosphorylation defect type 21 | no assertion criteria provided | research |